Efficacy and Safety of Human Bone Marrow Derived Mesenchymal Stem Cells according to Injection Route and Dose in a Chronic Kidney Disease Rat Model
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chae, Han Kyu | - |
dc.contributor.author | Suh, Nayoung | - |
dc.contributor.author | Jang, Myong Jin | - |
dc.contributor.author | Kim, Yu Seon | - |
dc.contributor.author | Kim, Bo Hyun | - |
dc.contributor.author | Aum, Joomin | - |
dc.contributor.author | Shin, Ha Chul | - |
dc.contributor.author | You, Dalsan | - |
dc.contributor.author | Hong, Bumsik | - |
dc.contributor.author | Park, Hyung Keun | - |
dc.contributor.author | Kim, Choung-Soo | - |
dc.date.accessioned | 2022-11-29T01:41:13Z | - |
dc.date.available | 2022-11-29T01:41:13Z | - |
dc.date.issued | 2022-04 | - |
dc.identifier.issn | 2005-3606 | - |
dc.identifier.issn | 2005-5447 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/21673 | - |
dc.description.abstract | Background and Objectives: We compared the efficacy and safety of human bone marrow-derived mesenchymal stem cells (hBMSC), delivered at different doses and via different injection routes in an animal model of chronic kidney disease. Methods and Results: A total of ninety 12-week-old rats underwent 5/6 nephrectomy and randomized among nine groups: sham, renal artery control (RA-C), tail vein control (TV-C), renal artery low dose (RA-LD) (0.5x10(6) cells), renal artery moderate dose (RA-MD) (1.0x10(6) cells), renal artery high dose (RA-HD) (2.0x10(6) cells), tail vein low dose (TV-ID) (0.5x10(6) cells), tail vein moderate dose (Tv-MI)) (1.0x10(6) cells), and tail vein high dose (TV-HD) (2.0x10(6) cells). Renal function and mortality of rats were evaluated after hBMSC injection. Serum blood urea nitrogen was significantly lower in the TV-HD group at 2 weeks (p<0.01), 16 weeks (p<0.05), and 24 weeks (p<0.01) than in the TV-C group, as determined by one-way ANOVA. Serum creatinine was significantly lower in the TV-HD group at 24 weeks (p<0.05). At 8 weeks, creatinine clearance was significantly higher in the TV-MD and TV-HD groups (p<0.01, p<0.05) than in the TV-C group. In the safety evaluation, we observed no significant difference among the groups. Conclusions: Our findings confirm the efficacy and safety of high dose (2x10(6) cells) injection of hBMSC via the tail vein. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Korean Society for Stem Cell Research | - |
dc.title | Efficacy and Safety of Human Bone Marrow Derived Mesenchymal Stem Cells according to Injection Route and Dose in a Chronic Kidney Disease Rat Model | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.15283/ijsc21146 | - |
dc.identifier.wosid | 000793226500001 | - |
dc.identifier.bibliographicCitation | International Journal of Stem Cells | - |
dc.citation.title | International Journal of Stem Cells | - |
dc.type.docType | Article; Early Access | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Cell & Tissue Engineering | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.subject.keywordPlus | STROMAL CELLS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | TRANSPLANTATION | - |
dc.subject.keywordPlus | LUNG | - |
dc.subject.keywordAuthor | Chronic kidney disease | - |
dc.subject.keywordAuthor | Stem cell transplantation | - |
dc.subject.keywordAuthor | Cell migration | - |
dc.subject.keywordAuthor | Bone marrow | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.